Podcasts about Hamilton

Hinch welcomes Will Buxton back on the show to chat about how he's finding things in his first year with IndyCar, now that the 500 is in the rear view mirror.+++Off Track is part of the SiriusXM Sports Podcast Network. If you enjoyed this episode and want to hear more, please give a 5-star rating and leave a review. Subscribe today wherever you stream your podcasts.Want some Off Track swag? Check out our store!Check out our website, www.askofftrack.comSubscribe to our YouTube Channel.Want some advice? Send your questions in for Ask Alex to AskOffTrack@gmail.comFollow us on Twitter at @askofftrack. Or individually at @Hinchtown, @AlexanderRossi, and @TheTimDurham.

⁠⁠⁠⁠⁠⁠⁠Get ad-free episodes, early release, and bonus shows⁠ The Turtle Lake Monster, Prince Albert Ghost Train, and a QAnon cult? That's right, the prairies are far stranger than you ever imagined. We've also got plenty of ghosts, including Brennan's trip to the very haunted Dundurn Castle in Hamilton, Ontario! Cover image by Dave Rheaume, who you can also follow on Instagram. The sketch was licensed via Adobe Stock Full shownotes @ GhostStoryGuys.com Learn more about your ad choices. Visit megaphone.fm/adchoices

C'mon, Fredrick -- it's time for this corpse flower to bloom! Prada debuts panty shorts, Jason gets back into his Peloton, Anthony Ramos dishes on Madonna -- who was on her tablet during "Hamilton?!"See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

“The Man-Trap” by Hamilton Craigie, first snapped its leaves in the November 1925 edition of Weird Tales Magazine. The tale was described as follows: “A monstrous plant makes its kill.”

From growing up in a modest neighborhood known as "Cardboard Village" in Oak Park, Michigan, to becoming one of the most influential producers in Broadway history, Jeffrey Seller's story is one of resilience, creativity, and a deep love of musical theater. In this candid and insightful conversation, Jeffrey reflects on the pivotal moments that shaped his journey—from the early days of Rent to launching Hamilton, and how he's always championed new voices that challenge the status quo. He opens up about his unique childhood, his bold choices as a young producer, and why he felt compelled to write his new memoir, Theater Kid. We talk about the emotional impact of revisiting his past, his creative process, and the behind-the-scenes decisions that brought shows like In the Heights, Avenue Q, and Hamilton to life. He also shares the significance of working in Times Square since 1986 and what it means to literally see his professional history from the studio window. Jeffrey's perspective is raw, honest, and deeply inspiring—a must-listen for anyone who loves theater and believes in the power of storytelling. Jeffrey Seller is a five-time Tony Award-winning producer behind landmark musicals including Rent, Avenue Q, In the Heights, and Hamilton. He also produced The Cher Show, De La Guarda, and The Inheritance, among others. He is the co-creator of Broadway's first ticket lottery and a champion for innovation in access and storytelling. His memoir Theater Kid chronicles his remarkable journey from Oak Park, Michigan, to the heights of Broadway. This episode is powered by WelcomeToTimesSquare.com, the billboard where you can be a star for a day. Connect with Jeffrey: Instagram: @sellerj Theater Kid (Memoir) – available wherever books are sold Connect with The Theatre Podcast: Support the podcast on Patreon and watch video versions of the episodes: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TheTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Twitter & Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@theatre_podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook.com/OfficialTheatrePodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TheTheatrePodcast.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Alan's personal Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@alanseales⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email me at feedback@thetheatrepodcast.com. I want to know what you think.

We're re-airing one of our most surprising and most popular episodes for you this week -- a deep dive into Aaron Burr from January 2023. This episode is guest-hosted by IEX's Jayme Abrahamsen and features Andy Kaplan (former Greenlight Capital partner, now CEO of Freedom's Edge Cider). In a previous episode, they broke down the mythology of Hamilton. This time, they turn the spotlight on his adversary, Aaron Burr. Vice President. Revolutionary War hero. Romance novel star. Duelist. Exile. They explore how Burr's legacy was rewritten by enemies like Hamilton and Jefferson, how he became a political cautionary tale, and what it says about who we choose to put on our currency and why.

Manny Schvartzman (Hamilton Music Director and Conductor) is back for round two as he continues discussing his experience putting up Rent in Cuba with Andy Señor, Jr in 2014. The whiplash of going from the shiny, multimillion dollar On Your Feet to a space with daily power outages and a lack of running water was an intense, rewarding, and life changing experience. It taught Manny that anything was possible, and theatre could truly be done absolutely anywhere. If he could do that, he could do anything. After Rent in Cuba and successfully adapting Gloria Estefan's music to a Broadway stage, Manny made his way to Hamilton, which he was a fan of "from day zero." Manny knew about Hamilton before any of us did, and being able to be a part of the show - and to work with his hero Alex Lacamoire - was beyond a dream come true. In this episode, Manny breaks down his super detailed job of Hamilton's music director (and conductor and keyboard player) and it takes us no time at all to become an Alex Lacamoire Appreciation Podcast, a very familiar topic on The Hamilcast. Manny on Instagram "Revolution Rent" Documentary directed by Andy Señor, Jr.  Carmen La Cubana: First Look! Hamilton's Alex Lacamoire Adapts Carmen For the Modern World Alex Lacamoire on The Hamilcast /// Gillian's Website The Hamilcast on Twitter The Hamilcast on Instagram Join the Patreon Peeps

Jeffrey Seller is an Tony Award-winning American theatrical producer best known for his work on Rent, Avenue Q, In the Heights, and Hamilton, as well as inventing Broadway's first rush ticket and lottery ticket policies. After graduating from the University of Michigan in 1986, Jeffrey moved to New York City where he worked, as a publicist, booking agent, and producer. With his business partner Kevin McCollum he produced three Best Musical Tony Award-winning Broadway shows; Rent, Avenue Q, and In the Heights. With increasingly expensive Broadway ticket prices, Seller and McCollum invented Broadway's first rush ticket policy early on in the production of Rent. The idea was to keep the show accessible for people “in their 20s and 30s, artists, Bohemians-the people for whom Jonathan Larson wrote the show.” A select number of front row tickets would be sold for $20 on a first come per-serve basis. Rush tickets became so popular that people began to sleep on the streets outside the theater to get a spot at the front of the line. Out of concern for the safety of those who participated in the Rush policy Seller and McCollum created Broadway's first lottery ticket policy, which kept cheap tickets accessible to a young audience by selling $20 tickets to the winners of a drawing. Together Seller and McCollum also produced De La Guarda, Andrew Lippa's The Wild Party, High Fidelity, and the revival of WestSide Story. After working with Lin-Manuel Miranda on In the Heights, he produced Hamilton. Hamilton has gone on to receive widespread critical acclaim and commercial success. In June 2016, Hamilton received 11 Tony awards of a record-breaking 16 nominations, including a Best Musical win for Seller, making it his fourth Tony Award. He is the author of the memoir, Theater Kid: A Broadway Memoir. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Bill Sherman wears many hats, including as the music director of "Sesame Street," orchestrating and arranging Broadway productions like "& Juliet," and "In The Heights," producing the "Hamilton" cast album, and also music director behind "Donkey Hodie," a puppet music video series for preschoolers on PBS Kids. Sherman discuss his career in music, and previews the second season of "Donkey Hodie," streaming this summer on PBS Kids and YouTube.

A sermon in our series, Habits: Healthy Habits of the Gospel-Formed Life.The Village Church is a community formed by the gospel and sent on God's mission to make, mature, and multiply disciples of Jesus. We gather in the heart of downtown Hamilton, Ohio, with the hope that God might be made known in every part of His city through every part of our lives.For more information about The Village, visit us online at myvillagechurch.com.

Averill's Book, Love in the Lav Series, Episode #2 of 4. In 1746, Charles Hamilton, a doctor, married Mary Price in Wells, England. Hamilton was a traveling doctor, selling patent medicines and dubious medical advice, and had met Mary when staying in a rented room. After the wedding, Mary joined Charles in traveling and selling cures for a couple of months until suddenly, she decided she no longer wanted to be married – and to get out of the relationship, Mary went to the local court and reported that her husband Charles Hamilton was, in fact, a woman. The revelation that Hamilton was assigned female at birth but lived their life as a man enchanted the public, and, as much as something could in the 18th century, went viral. Hamilton's story was then immortalized in a fictionalized story called The Female Husband. Thus, the concept of a “female husband,” or a person assigned female at birth but living as a man, including serving as a husband, entered into the consciousness of the Anglo-American world. The history of female husbands like Charles Hamilton and many others prove not only that queerness has always existed, but that gender itself has always has been messy, flexible, and contested. Bibliography Manion, Jen. Female Husbands: A Trans History. Cambridge: Cambridge University Press, 2020 Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mass readings for Corpus Christi – 6/22/25 Reading 1, Genesis 14:18-20 Responsorial Psalm, Psalms 110:1, 2, 3, 4 Reading 2, First Corinthians 11:23-26 Gospel, Luke 9:11-17

' Feudin' and fussin' and fightin'--on-stage and off-stage: West Side Story, Hamilton, Camelot and two gals named Patti and Audra.

On Friday's Mark Levin Show, there's the horseshoe theory against Israel on Iran, which says that the radical left and right political ideologies, such as radical leftists (e.g., Communists, Islamists) and far-right groups (e.g., Klansmen, white supremacists, neo-Nazis, isolationists), converge in their views and actions, forming an alliance despite apparent differences. That's why we see Bernie Sanders agree with Chatsworth Qatarlson (Tucker Carlson) and Steve Bannon. Bannon claims Mark Levin, Sean Hannity, Kayleigh McEnany, and Fox News should be investigated for supporting Israel. One would think he would be careful about saying who should be investigated after his past. Matt Gaetz is back saying that Israel doesn't allow Arabs to vote, which is a flat-out lie.  As time goes on these people all reveal themselves as the crazy people they are with no loyalty to President Trump or MAGA. Also, Trump is a historic figure leading efforts to counter Iran's nuclear ambitions. Israel's military actions, including destroying Iranian radar and weakening their defenses, make it easier for U.S. or Israeli forces to strike nuclear sites like Fordo. Americans are not warmongers or neo-cons. The American public supports these actions, rejects isolationism, and opposes being labeled warmongers by “fake MAGA” critics. Later, Gov Ron DeSantis calls in to explain Florida's efforts to evacuate Americans in Israel. The state evacuated 1,500 people, including college students and families, with two planeloads of 160-170 passengers already returned to Tampa. He emphasized the emotional relief of families, particularly those with young children, and Florida's commitment to continue the mission, utilizing resources like cruise ships to Cyprus for safe transport. DeSantis also discusses his push to reform property taxes in Florida, focusing on exempting primary residences (homesteaded properties) from property taxes. Homeowners don't truly own their homes if they must continuously pay property taxes, as failure to pay could result in government seizure. Finally, Alexander Hamilton's view of liberty and government contrasted sharply with that of Thomas Jefferson and James Madison, favoring a stronger, more centralized federal authority. While Madison, in Federalist No. 45, emphasized that the Constitution granted the federal government limited, defined powers—primarily over external affairs like war and foreign commerce—leaving broad authority to the states, Hamilton advocated for a more robust national government. At the Constitutional Convention, he proposed a powerful executive and legislature with lifelong terms, reflecting his preference for centralized control, though these ideas were swiftly rejected. Despite his role in co-authoring the Federalist Papers to support the Constitution's ratification, Hamilton's vision aligns with modern proponents of an activist government, contributing to his popularity among contemporary elites in media, politics, and academia, as evidenced by Hamilton the musical. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mark Twain didn't just write American classics, he lived one of the most powerful personal transformations in history. In Part 2 of this conversation, Pulitzer Prize-winning biographer Ron Chernow returns to join Ryan for a deep dive into Twain's remarkable moral evolution. They discuss how Twain's journey mirrors those of Ulysses S. Grant and John D. Rockefeller, reflect on the tragic cost of chasing fortune over purpose, and explore what makes a biography timeless and a life unforgettable.Plus, a special moment: Ryan's 8-year-old son jumps in to ask Ron about Hamilton, his favorite musical.Ron Chernow is the prizewinning author of seven previous books and the recipient of the 2015 National Humanities Medal. His first book, The House of Morgan, won the National Book Award, Washington: A Life won the Pulitzer Prize for Biography, and Alexander Hamilton—the inspiration for the Broadway musical—won the George Washington Book Prize. He has twice been a finalist for the National Book Critics Circle Award and is one of only three living biographers to have won the Gold Medal for Biography of the American Academy of Arts and Letters. Ron's latest book is on the fascinating and complex life of American writer Mark Twain. Follow Ron Chernow on Instagram: @RonChernow

Welcome to The Capitol Hoops Summer League @ DeMatha Summer Series of The DMV Hoops Podcast.  We are broadcasting from DeMatha Catholic HS, for the entirety of the 2025 Summer League.  Check in with us throughout the summer for player & coach interviews, live look-ins & more!In this episode, we sit down with Virginia Academy Head Coach, Tau Hamilton.  Coach Hamilton joins the broadcast table with us to discuss...From the Dr. J Hoop until now, his basketball journeyHow basketball is the "vehicle" to his mentorshipAdvancing the athlete's life, outside of sportsListen to all of this & more in this episode of "The DMV Hoops Podcast."Kurt Cross - Producer & Host | Adam Crain - On Air TalentFollow On InstagramFollow On X/TwitterSports, DMV, Basketball, Kurt Cross, Hoops, Adam Crain, DMV Hoops, AAU, Capitol Hoops, Summer League, Virginia Academy, Tau HamiltonSupport the show

Looking for unique and authentic F1 merchandise? Check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠www.racingexclusives.com⁠⁠⁠⁠⁠⁠⁠⁠⁠! Check out The RaceWknd magazine ⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠! Title music created by J.T. the Human: https://www.jtthehuman.com/ Contact & Feedback: Find us on Apple Podcasts, Spotify or wherever you enjoy podcasts Email: scuderiaf1pod@gmail.com X: @ScuderiaF1Pod Episode Show Notes: June 19th, 2025 Welcome back to the Scuderia F1 Podcast! We've got a packed rundown of the biggest stories for you this week. A shock resignation has thrown one team's future into doubt, the 2026 driver market is already kicking off with a huge rumor, and F1 continues its global expansion with a multi-billion dollar bid for a new race. Here are the details you need to know: SHAKE-UP AT ALPINE: Renault's CEO is out! 1 Luca de Meo's shock resignation puts the F1 team's long-term future in doubt. 2 RUSSELL TO ASTON?: The 2026 silly season may have already begun, with reports that Aston Martin is targeting George Russell. But Russell himself says he's not talking with any other team and remains loyal to Mercedes. ROSBERG'S WARNING: After a costly crash in Canada, 2016 champion Nico Rosberg warns Lando Norris of the "dark mental spiral" that can follow repeated high-pressure mistakes. F1 EXPANDS: The Canadian Grand Prix is locked in until 2035, and Thailand has officially tabled a massive $1.2 billion bid to bring a street race to Bangkok. HAMILTON'S HISTORIC SLUMP: For the first time in his career, Lewis Hamilton has gone 10 races into a season without a podium finish. 3 LIGHTS, CAMERA, ACTION!: The new F1 movie drops next week. 4 Initial reviews are strong with an 84% on Rotten Tomatoes and an "AMAZING" haptic trailer. 5 QUICK HITS: Robert Kubica was victorious at the Le Mans 24 hours 6 and Abbi Pulling is set to join the Nissan Formula E Team as a rookie driver. 7 So there you have it—a week of major shake-ups, from the management suites to the driver market. The pressure is on for Norris, Hamilton is chasing that elusive podium, and the grid of the future is already taking shape. Up next, we'll break down what all this means as we look ahead to the next race weekend. Stick with us. Join the conversation! Follow us on X @ScuderiaF1Pod Subscribe to the Scuderia F1 Podcast wherever you get your podcasts. Please leave us a rating and review if you enjoyed the show! Thanks for tuning in! Learn more about your ad choices. Visit megaphone.fm/adchoices

The Best Hang prepares for Hamilton's biggest event, “Arkells: The Rally”! The guys discuss the Best Hang pop-up at the Rally Market on Sat 11a-4p, where Mike and Shane will be hanging out with a limited number of Shirts & Hats! Also, we dive into the new Bruce Springsteen bio-pic trailer, Stephen King, and Mike shares his thoughts on the new movie, “The Life of Chuck”. Hosted on Acast. See acast.com/privacy for more information.

Is the Genius Act a covert attack on Bitcoin—or the spark that sends it to all-time highs? Parker Lewis and Hamilton dive into what this legislation really means for Bitcoin's future and why it has everyone talking.FOLLOW TODAY'S PANELISTS:https://x.com/parkeralewishttps://x.com/Rob1Hamhttps://x.com/Meditation_ManFOLLOW BTC SESSIONS on X/Nostr: x.com/BTCsessionsbtcsessions@getalby.comBOOK private one-on-one sessions with BITCOIN MENTOR! Learn self custody, hardware, multisig, lightning, privacy, running a node, and plenty more - all from a team of top notch educators that I've personally vetted.https://bitcoinmentor.io/—------------------------------SHOW SPONSORS:BITCOIN WELL - BUY BITCOINhttps://qrco.de/bfiDC6COINKITE/COLDCARD (5% discount):https://qrco.de/bfiDBVAQUA WALLEThttps://qrco.de/bfiD8gNUNCHUK HONEYBADGER INHERITANCEhttps://qrco.de/bfiDARHODLHODL NO KYC P2P EXCHANGEhttps://hodlhodl.com/join/BTCSESSIONDEBIFI LOANShttps://qrco.de/bfiDCpCRYPTOCLOAKShttps://qrco.de/bg5Dvo#btc #bitcoin #crypto

The co-hosts weigh in on Pres. Trump becoming the first president to not be invited to the NAACP convention. Then, they react to a tourist breaking Nicola Bolla's "Van Gogh" crystal covered chair after sitting on it in the Palazzo Maffei Museum in Verona, Italy. Texas Representative Jasmine Crockett joins “The View” to discuss Juneteenth's roots in her home state and she reacts to a wave of political violence in America. Renée Elise Goldsberry, who played Angelica Schuyler in the original Broadway production of “Hamilton,” discusses the show's enduring success and performs “Satisfied” from her debut album, “Who I Really Am.” Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hinch and Rossi recap a banger of a Bommarito Automotive Group 500 at Gateway, including the explosions that started it off, the bad luck a few drivers had, and the great racing we all got to watch.+++Off Track is part of the SiriusXM Sports Podcast Network. If you enjoyed this episode and want to hear more, please give a 5-star rating and leave a review. Subscribe today wherever you stream your podcasts.Want some Off Track swag? Check out our store!Check out our website, www.askofftrack.comSubscribe to our YouTube Channel.Want some advice? Send your questions in for Ask Alex to AskOffTrack@gmail.comFollow us on Twitter at @askofftrack. Or individually at @Hinchtown, @AlexanderRossi, and @TheTimDurham.

In today's episode, we have Carol Hamilton, Chief Product and Strategy Officer at Provenird. She discusses how AI-powered decisioning platforms are transforming risk management across financial services. She explores the critical balance financial institutions must strike between managing evolving risk threats and maintaining seamless customer experiences, a challenge that has become increasingly complex in today's uncertain macroeconomic environment. She explains how Provenir's platform helps organizations make intelligent decisions across the entire customer lifecycle, from onboarding and fraud prevention to collections, by orchestrating real-time data and AI to provide contextual insights that enable both risk mitigation and opportunity optimization. The conversation delves into key findings from Provenir's 2025 Global Risk Decisioning Survey, revealing that over half of respondents struggle with data integration, while 60% find it difficult to deploy and maintain risk models. Hamilton emphasizes how generative AI is being leveraged not just as a trend but to drive tangible outcomes, speeding up decision-making processes, enhancing model explainability, and analyzing unstructured data. Looking ahead, she describes 2025 as "the year of intelligent decisioning," where organizations can move beyond traditional rules-based systems to achieve the perfect contextual understanding needed for hyper-personalized customer interactions that unlock value while effectively managing risk.In this podcast you will learn:What Provenir does exactly.The types of risk decisions they help their customers make.The biggest pain points in risk management for financial institutions today.The different geographies where Provenir operates.Why they have focused on enterprise businesses.How they approach the tension between preventing fraud and seamless customer experiences.How their clients are managing risks in today's uncertain environment.The different types of simulations they can run inside their platform.How they are using generative AI in their decisioning engine.How their approach differs from others in the market.The purpose of their 2025 Global Risk Decisioning Survey.Some the of the core findings from the survey.How they help their clients deploy their risk decisioning models.How they are working with lenders with credit risk and detecting fraud.What they mean by calling 2025 the “year of intelligent decisioning.”How they approach product development given the different needs of their customers.What is next for Provenir.Connect with Fintech One-on-One: Tweet me @PeterRenton Connect with me on LinkedIn Find previous Fintech One-on-One episodes

Hochul is warning of extreme heat this week... Juneteenth celebrations kick off today... Self-driving cars could soon hit NYC streets... Hamilton's original cast recording gets a boost from the Tony Awards full 440 Thu, 19 Jun 2025 09:55:31 +0000 FrOwMTvUzp2EFeq7pGAWE2lLD2lukldV news 1010 WINS ALL LOCAL news Hochul is warning of extreme heat this week... Juneteenth celebrations kick off today... Self-driving cars could soon hit NYC streets... Hamilton's original cast recording gets a boost from the Tony Awards The podcast is hyper-focused on local news, issues and events in the New York City area. This podcast's purpose is to give New Yorkers New York news about their neighborhoods and shine a light on the issues happening in their backyard. 2024 © 2021 Audacy, Inc.

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Wednesday, June 04, 2025 The Dominant Duo – Total Dominance Hour -Gideon Hamilton for Jim, OU and Thunder comparisons, favorites next year, GO win! and more. Follow the Sports Animal on Facebook, Instagram and X PLUS Jim Traber on Instagram, Berry Tramel on X and Dean Blevins on X Follow Tony Z on Instagram and Facebook Listen to past episodes HERE! Follow Total Dominance Podcasts on Apple, Google and SpotifySee omnystudio.com/listener for privacy information.

Hello sailor! Welcome to Wednesday's episode. The heat is getting to Jane and Fi... they chat Dubai chocolate, hanxiety, and fridge magnets. Plus, former sub-postmaster Jo Hamilton speaks about her book 'Why Are You Here, Mrs Hamilton?: The Post Office Scandal and My Extraordinary Fight for Justice'. If you want to come and see us at Fringe by the Sea, you can buy tickets here: www.fringebythesea.com/fi-jane-and-judy-murray/ And if you fancy sending us a postcard, the address is: Jane and FiTimes Radio, News UK1 London Bridge StreetLondonSE1 9GFIf you want to contact the show to ask a question and get involved in the conversation then please email us: janeandfi@times.radioThe next book club pick has been announced! We'll be reading Leonard and Hungry Paul by Rónán Hession.Follow us on Instagram! @janeandfiPodcast Producer: Eve SalusburyExecutive Producer: Rosie Cutler Hosted on Acast. See acast.com/privacy for more information.

Another week and another win! It wasn't pretty but the guys are back to go over the Riders week 2 victory! Alex, Greg, and Steve reflect back on the Riders win in Hamilton. From how great the O-line looked to how not great Brett Lauther looked to who is still healthy and who in not.  In the Odds and End Zones, the Hall of Fame announcements were made and there are Saskatchewan ties, some better than others. Plus a look at the other week 2 games and what BC is doing to get more fans in the building.  Then the guys look ahead to the game versus the Argos and try to be perfect in Piffles Picks. 

An interview with one of the collective members behind Black Oak Anarchist Social Space, which launched in Hamilton in Spring 2025.  LINKS Black Oak Anarchist Social Space Hamilton Anarchist Bookfair North Shore Counter-Info RELATED EPISODES The Locke Street Affair (Part 1) Queers Fight Back Cedar on #FreeCedar Five Years After The Brawl At Hamilton Pride MUSIC Ant.Survila - Nostalgic Reflections 

David Malukas swings by to talk about how his season is going with Foyt, his social media presence, the pressure of dealing with the rumors and more.+++Off Track is part of the SiriusXM Sports Podcast Network. If you enjoyed this episode and want to hear more, please give a 5-star rating and leave a review. Subscribe today wherever you stream your podcasts.Want some Off Track swag? Check out our store!Check out our website, www.askofftrack.comSubscribe to our YouTube Channel.Want some advice? Send your questions in for Ask Alex to AskOffTrack@gmail.comFollow us on Twitter at @askofftrack. Or individually at @Hinchtown, @AlexanderRossi, and @TheTimDurham.

Henry tackles the films of director Tom Hooper including The King's Speech, Les Misérables (2012), The Danish Girl, and Cats (2019), plus BONUS reviews of Eddie Redmayne's The Theory of Everything, Hugh Jackman's The Greatest Showman, and Disney's Hamilton (2020).0:00 - Intro1:32 - The King's Speech12:31 - Les Misérables22:43 - The Danish Girl32:07 - Cats40:45 - The Theory of Everything51:19 - The Greatest Showman56:39 - Hamilton1:04:12- OutroFollow Film Buds:LinktreeFaceBookTwitter / XInstagramYouTubeWebsiteFollow Henry & Elle on Letterboxd:Henry's ProfileElle's ProfileBuy Our Premium Podcasts:BandcampSponsors / Inquiries:FilmBudsPodcast@gmail.com

Tony Award-winner Renée Elise Goldsberry has released her debut album, Who I Really Am, coinciding with the tenth anniversary of "Hamilton" on Broadway. Goldsberry joins for a Listening Party, and discusses playing Angelica Schuyler a decade ago.

Rachel talks about why people love or hate musicals, Crazy Ex- Girlfriend and how it would never be made today and how unlikely it was to get made back then.  She also talks about growing up in Manhattan Beach, Theater School in NY, not having billionaire friends, enjoying the now, writing her one woman show to get through the death of Adam Schlessenger and the birth of her daughter, how being married to a funny person can help, Hamilton, The Tony Awards, the amazing last year of Crazy Ex-Girlfriend, the magic of musical, theater, and having a stand-up comic/Hughes Aircraft Engineer grandpa. Bio:  RACHEL BLOOM is perhaps best known from the CW musical dramedy Crazy Ex-Girlfriend, which she co-created, executive produced, and starred in as ‘Rebecca Bunch.' For her acting work on the show, she was awarded a Golden Globe, Critics' Choice and TCA Award; for her songwriting work, she won an Emmy Award for Original Music and Lyrics along with her songwriting partners Adam Schlesinger and Jack Dolgen. Most recently, Bloom debuted her Drama Desk nominated, sold-out, four-week off Broadway one-woman musical comedy Death, Let Me Do My Show which she originally toured around London and the US. It was then released on Netflix as a comedy special Death, Let Me Do My Special and nominated for a Critic's Choice Award. She also co-starred in the Hulu comedy series Reboot and the second season of the Max series, Julia. Her past stage work includes selling out Radio City Music Hall and the London Palladium performing Crazy Ex-Girlfriend: LIVE. She also starred in her own solo tour, What Am I Going To Do With My Life Now? in 2019, which included a week-long residency at Just For Laughs. In addition, she appeared in a one-night only production of Crazy For You at Lincoln Center directed by Susan Stroman. In addition to her film and television work, in 2020, she published her book “I Want To Be Where The Normal People Are,” a collection of personal essays and poems on the subjects of insecurity, fame, anxiety, and much more.

Send us a message with feedback or questions!Welcome to the latest episode of The Florida Project – the podcast where Disney fans celebrate Walt Disney World and all things Disney! In this episode, we'll discuss some nonsense in small topics, Michael will give us some Disney movie news, and then we'll discuss our most recent trip to Walt Disney World with two teenagers! All of that and more is coming up in this week's episode of The Florida Project!-- Recorded on June 13, 2025Small TopicsThe Tony's were this week. What should Disney on Broadway's next production be? It can be an existing property or something new.Hamilton celebrated it's 10-year anniversary this year with a live mix-tape performance by the original Broadway cast. I don't really have a question but Hamilton was really good, right? Let's talk about it.What is your biggest road-trip pet peeve?Movie NewsDisney/Pixar AnimationDiscussion TopicTrip Review: Early Summer at Walt Disney WorldUpcoming EpisodesTBD (next week)PlugsJason: @Schmuck00Will: @ThyWillBDunnMichael: @MichaelMcDuckSite: http://www.tfppodcast.comBluesky: https://bsky.app/profile/tfppodcast.bsky.socialInstagram: http://instagram.com/tfppodcastThreads: https://www.threads.net/@tfppodcastPatreon: http://www.patreon.com/tfppodcastSupport the show

I hope you're ready for a deep dive on Team Music because Manny Schvartzman is here! Manny is the music director, conductor, and keyboard one player on Hamilton's Angelica Tour. In his first episode, Manny walks us through the early stages of his career, which started at around eight years old, when he started teaching himself to play piano and read music with the goal of being a classical pianist. By the time he was a freshman in high school, the word was out in Miami about kid from Buenos Aires who could play piano like nobody's business. Manny was like Schroeder - all about the classical music - and he couldn't be bothered with musicals like Fiddler on the Roof. But once he got a taste of the collaboration and storytelling involved in the theatre world, he never looked back.  Being his high school's music director at 14 years old was a formative experience and then you combine it with Manny's inherent curiosity, kindness, and relentless work ethic? He's unstoppable.  Manny was summoned to New York to work on On Your Feet (with the legendary Gloria Estefan) and was simultaneously making history in 2014 when he was part of the team that brought Cuba its first Broadway musical in 50 years: RENT. Manny on Instagram "Revolution Rent" Documentary directed by Andy Señor, Jr.  /// Gillian's Website The Hamilcast on Twitter The Hamilcast on Instagram Join the Patreon Peeps

No one tells you that joy and grief can live in the same moment, especially when you become a grandmother. In this powerful conversation, Heather sits down with Kellie Hamilton to unpack the emotional transition of watching your daughter become a mother. What begins as pride can unexpectedly stir up loss, identity shifts, and a quiet grief that no one warns you about. Together, Heather and Kellie dive into:

Looking for unique and authentic F1 merchandise? Check out ⁠⁠⁠⁠⁠⁠⁠www.racingexclusives.com⁠⁠⁠⁠⁠⁠⁠! Check out The RaceWknd magazine ⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠! Title music created by J.T. the Human: https://www.jtthehuman.com/ Contact & Feedback: Find us on Apple Podcasts, Spotify or wherever you enjoy podcasts Email: scuderiaf1pod@gmail.com X: @ScuderiaF1Pod Episode Show Notes: June 12th, 2025 As the F1 world descends on Montreal, the biggest debate is about the future, not the present. The crew dives headfirst into the controversial 2026 calendar that sees the historic Imola circuit axed in favor of a new street race in Madrid. This move has drawn fiery criticism from Lewis Hamilton, and we break down both sides: Is this a necessary evolution for F1's global brand, or is the sport trading its soul for new markets? We discuss Hamilton's pointed critique and what it means when a seven-time champion publicly questions the sport's direction. The drama doesn't stop there. We cover all the latest news ahead of the Canadian Grand Prix, including Lance Stroll's confirmation at Aston Martin just in time for his home race and HAAS's 200th GP celebration. The team also touches on the unique haptic trailer for the upcoming 'F1' movie, Red Bull's 17-year-old phenom getting his Super License, the mounting pressure on Franco Colapinto, and Ford's electric ultimatum for its future in the sport. Join the conversation! Follow us on X @ScuderiaF1Pod Subscribe to the Scuderia F1 Podcast wherever you get your podcasts. Please leave us a rating and review if you enjoyed the show! Thanks for tuning in! Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Packernet After Dark, we dive deep into the aftermath of Jaire Alexander's release and what it means for the Packers' cap and future. Listeners call in to dissect everything from Green Bay's salary cap flexibility to the depth and development of our cornerbacks. Is the panic around 2026's cap justified? Are fans underrating Carrington Valentine and the DB room? Plus, a hilarious chicken joke, a Hamilton reference, and a glimpse into NFC North predictions. It's a passionate, unfiltered, and surprisingly funny night with the Packernet faithful. To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast

Pantsuit Politics is celebrating ten years of podcasting this year! A lot has happened politically, culturally, and personally in the last ten years. This summer, we’re revisiting each of the years we’ve been podcasting with a special flashback episode. Today, we continue the conversation by looking at 2016. Topics Discussed The Biggest News Stories of 2016: The Presidential Election, Brexit, and the MAGA takeover of the Republican Party Outside of Politics: Cultural Highlights of 2016: Hamilton and Lemonade Visit our website for complete show notes, premium shows, show merchandise, and more.See omnystudio.com/listener for privacy information.